DNA methylation of glioma related gene and its significance

doi:10.3760/cma.j.issn.1673-422X.2015.10.012

Abstract

Abstract: DNA methylation is closely related to the genesis and development of glioma. The CpG islands hypermethylation in promoter region of DNA repair genes, cell cycle controlling genes, apoptosis related genes, tumor suppressor genes and invasion related genes are found in glioma. Finding the specific methylation profile and molecular marker of glioma is helpful for the pathology class, early diagnosis and prognostic evaluation. Meanwhile, DNA methylation has the characteristic of reversibility, which may provide new ways for the treatment of glioma.

Key words: Glioma, DNA methylation

Yan Xiaoguang, Hua Dingchao, Guo Geng, Lu Chenyang. DNA methylation of glioma related gene and its significance[J]. Journal of International Oncology, 2015, 42(10): 762-765.

References

［1］ Bicker J, Alves G, Fortuna A, et al. Bloodbrain barrier models and their relevance for a successful development of CNS drug delivery systems: a review［J］. Eur J Pharm Biopharm, 2014, 87(3): 409-432. ［2］董方, 薛金才, 王小虎. 恶性脑胶质瘤的综合治疗［J］. 国际肿瘤学杂志, 2014, 41(11): 816-820. ［3］ Westphal M, Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches［J］. Nat Rev Neurosci, 2011, 12(9): 495-508. ［4］ Kreth S, Thon N, Kreth FW. Epigenetics in human gliomas［J］. Cancer Lett, 2014, 342(2): 185-192. ［5］ Kanemoto M, Shirahata M, Nakauma A, et al. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region［J］. BMC Cancer, 2014, 14: 641. ［6］ Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of highgrade gliomas in children: a report from the Children′s Oncology Group［J］. Neuro Oncol, 2011, 13(3): 317-323. ［7］ Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5year analysis of the EORTCNCIC trial［J］. Lancet Oncol, 2009, 10(5): 459-466. ［8］ Kreth S, Thon N, Eigenbrod S, et al. OmethylguanineDNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation［J］. PLoS One, 2011, 6(2): e17156. ［9］ FerrerLuna R, Núez L, Piquer J, et al. Wholegenomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles［J］. J Neurooncol, 2011, 103(1): 71-85. ［10］ Feng J, Kim ST, Liu W, et al. An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma［J］. Cancer, 2012, 118(1): 232-240. ［11］ Sibin MK, Bhat DI, Narasingarao KV, et al. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant highgrade glioma［J］. Tumour Biol, 2015, In press. ［12］ Kuo LT, Tsai SY, Chang CC, et al. Genetic and epigenetic alterations in primaryprogressive paired oligodendroglial tumors［J］. PLoS One, 2013, 8(6): e67139. ［13］ Zheng S, Houseman EA, Morrison Z, et al. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression［J］. Neuro Oncol, 2011, 13(3): 280-289. ［14］ Ramirez JL, Taron M, Balaa C, et al. Serum DNA as a tool for cancer patient management［J］. Rocz Akad Med Bialymst, 2003, 48: 34-41. ［15］ Hesson L, Bièche I, Krex D, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas［J］. Oncogene, 2004, 23(13): 2408-2419. ［16］ MajchrzakCelińska A, Paluszczak J, Szalata M, et al. The methylation of a panel of genes differentiates lowgrade from highgrade gliomas［J］. Tumour Biol, 2015, 36(5): 3831-3841. ［17］ Kosla K, Pluciennik E, Kurzyk A, et al. Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme［J］. J Neurooncol, 2011, 101(2): 207-213. ［18］ Agnihotri S, Wolf A, Munoz DM, et al. A GATA4regulated tumor suppressor network represses formation of malignant human astrocytomas［J］. J Exp Med, 2011, 208(4): 689-702. ［19］ Vaitkiené P, Skiriuté D, Skauminas K, et al. GATA4 and DcR1 methylation in glioblastomas［J］. Diagn Pathol, 2013, 8: 7. ［20］ Skiriuté D, Steponaitis G, Vaitkiené P, et al. Glioma malignancydependent NDRG2 gene methylation and downregulation correlates with poor patient outcome［J］. J Cancer, 2014, 5(6): 446-456. ［21］ Jiang Z, Zhou W, Li XG, et al. The methylation analysis of EMP3 and PCDHgammaA11 gene in human glioma［J］. Zhonghua Wai Ke Za Zhi, 2010, 48(4): 300-304. ［22］ Lindemann C, Hackmann O, Delic S, et al. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation［J］. Acta Neuropathol, 2011, 122(2): 241-251. ［23］ Alonso MM, DiezValle R, Manterola L, et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas［J］. PLoS One, 2011, 6(11): e26740. ［24］ Liu BL, Cheng JX, Zhang W, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas［J］. Neuro Oncol, 2010, 12(6): 540-548. ［25］ Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets［J］. Nat Biotechnol, 2010, 28(10): 1069-1078.

[1]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[2]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[3]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[4]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[5]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[6]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.
[7]	Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma [J]. Journal of International Oncology, 2021, 48(3): 172-175.
[8]	Deng Bo'er, Kong Weimin. Epigenetic research progress of endometrial cancer [J]. Journal of International Oncology, 2021, 48(3): 184-188.
[9]	He Miao, Fan Kui, Cao Fang. Epigenetics and drug resistance in lung cancer [J]. Journal of International Oncology, 2021, 48(10): 622-626.
[10]	Sang Yingbing, Liang Junqin. Epigenetic pathogenesis of cutaneous squamous cell carcinoma [J]. Journal of International Oncology, 2020, 47(9): 569-572.
[11]	Zhao Congxuan, Yu Tao. Mining and prediction of glioma-related genes [J]. Journal of International Oncology, 2020, 47(5): 293-296.
[12]	Nan Yang, Zhong Yue. New research advances of long non-coding RNA in glioma [J]. Journal of International Oncology, 2020, 47(2): 98-102.
[13]	Zhang Wen, Song Qibin, Hu Weiguo. Clinical application of multimodal magnetic resonance imaging in glioma [J]. Journal of International Oncology, 2020, 47(11): 686-690.
[14]	Chen Liang, Qin Jun, Lei Junrong, Liu Jun, Wang Lu. miR-1254 inhibits the proliferation and invasion of glioma cells by targeting CSF-1 [J]. Journal of International Oncology, 2020, 47(10): 577-584.
[15]	Zhang Qianhui, Zhang Yang, Su Weipeng, Zhang Song′an, Liu Pan, Zhao Huarong. Expressions of LSD1, MGMT and Ki-67 in high-grade glioma and their influences on prognosis [J]. Journal of International Oncology, 2019, 46(9): 519-525.